SEC Form 4 · accession 0001140361-18-019388
Loxo Oncology, Inc. · LOXO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Lori Anne Kunkel
Director
Period of report
Apr 20, 2018
Accepted (ET)
Apr 24, 2018 · 4:30 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001581720
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2,F3 | Apr 20, 2018 | S | 900 | $131.9772 | D | 10,940 | D | |
| Common StockF2,F4 | Apr 20, 2018 | S | 4,000 | $132.8097 | D | 6,940 | D | |
| Common Stock | Apr 20, 2018 | S | 100 | $133.60 | D | 6,840 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The transaction reported on this Form 4 was effected pursuant to a 10b5-1 trading plan adopted by the reporting person on June 20, 2017.
- F2Represents the aggregate of sales effected on the same day at different prices.
- F3Represents the weighted average sales price per share. The shares sold at prices ranging from $131.22 to $132.21 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- F4Represents the weighted average sales price per share. The shares sold at prices ranging from $132.55 to $133.36 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.